Businesses
We concentrate on vaccines, and have a focus on major innovative vaccines. with independent. intellectual property rights
All categories

Enterprise Milestone

2011

On March 7, 2011, Beijing ABZYMO Biosciences Co., Ltd. was established.

2012

On May 18, 2012, Jiangsu Rec-Biotechnology Co., Ltd. was established and settled in the Vaccine Engineering Center of China Medical City.

2012

In 2012, RecBio and Beijing ABZYMO Biosciences Co., Ltd. signed the Cooperation Agreement on HPV Preventive Vaccine (Recombinant Hansenula Polymorpha).

2015

On July 7, 2015, the application for clinical trial of recombinant bivalent HPV-16/18 vaccine (Hansenula polymorpha) was accepted.

2016

On April 18, 2016, the application for clinical trial of recombinant bivalent HPV-6/11 vaccine (Hansenula polymorpha) was accepted.

2017

On October 19, 2017, the approval for clinical trial of recombinant bivalent HPV-16/18 vaccine (Hansenula polymorpha) was obtained.

2017

On December 25, 2017, the application for clinical trial of recombinant 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58) (Hansenula polymorpha) was accepted.

2018

On May 31, 2018, the approval for clinical trial of recombinant bivalent HPV-6/11 vaccine (Hansenula polymorpha) was obtained.

2018

On July 6, 2018, the approval for clinical trial of recombinant 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58) (Hansenula polymorpha) was obtained.

2019

On January 11, 2019, RecBio merged with Beijing ABZYMO Biosciences Co., Ltd.

2019

On January 24, 2019, RecBio completed Round A financing of RMB 500 million.

2019

On March 28, 2019, the Phase I clinical trial of recombinant 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58) (Hansenula polymorpha) was initiated.

2020

On May 18, 2020, the construction of RecBio HPV vaccine industrialization project production base was started.

2020

In November 2020, RecBio completed Round B financing of more than USD 100 million.

2020

On November 23, 2020, the COVID-19 vaccine industrialization project of RecBio was started.
  • TOP   

Contact Us

Jiangsu Rec-Biotechnology Co., Ltd.

tel:+86-523-86818860

 

Address: Vaccine Engineering Center, China Medical City, Taizhou

Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd.  All rights reserved.      苏ICP备19043567号-1